Missed this series? Recording available! 

Learn more about our unique funding program! 

Latest FDA Approvals

• December 1 -FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma 
• November 27 -FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphomaFDA approves nirogacestat for desmoid tumors 
• November 16 - FDA approves capivasertib with fulvestrant for breast cancer
• November 16 - FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
• November 16 - FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma | FDA
• November 15 - FDA approves repotrectinib for ROS1-positive non-small cell lung cancer | FDA
• Oct 31 - FDA approves pembrolizumab with chemotherapy for biliary tract cancer
• Oct 27 - FDA approves toripalimab-tpzi for nasopharyngeal carcinoma
• Oct 24 - FDA approves ivosidenib for myelodysplastic syndromes
• Oct 20 - FDA expands pediatric indication for entrectinib and approves new pellet formulation
• Oct 16 - FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
• Oct 13 - FDA approves nivolumab for adjuvant treatment of Stage IIB/C melanoma
• Oct. 11 - FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation 

• Sept. 26 - FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia

• Sept. 14 - FDA approves new and updated indications for temozolomide under Project Renewal 

Package/Label Updates

• August - FDA approves new indication for  anemia without previous erythropoiesis stimulating agent use (ESAnaïve) in adult patients with very low-to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions

Other Updates

Enjoy this wonderful interview with 3 of NNECOS' founding members!

• UVM Cancer Center - Academic Clinician with experience in solid tumor oncology and immunotherapy

• UVM Cancer Center - Tenure-track faculty member-Assistant Professor level.

• UVM Cancer Center - Classical and Malignant Hematologist 

• UVM Medical Center - Clinical Program Coordinator - Hematology